Lupin receives US FDA Approval for Novel Formulation of Suprax® Suspension

BSE: 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Mumbai, 12 April 2007: Lupin Ltd. announced today that the U.S. Food and Drug Administration (US FDA) has approved the Company's application for Suprax® Cefixime for oral suspension 200mg/5ml. Commercial shipments of the product have commenced.

This novel formulation of Suprax® is a line extension of Lupin's flagship anti-infective brand Suprax® Cefixime for oral suspension 100mg/5ml. The higher concentration formulation allows parents to administer fewer teaspoons per dose of the antibiotic to their children. When using the novel dose, parents would need to administer only half the volume of the existing 100mg/5ml suspension.

"The approval of our Cefixime for oral suspension 200mg/5ml product enables the launch of this important line extension to our brand Suprax® in the US and allows us to increase our share of the cephalosporin oral suspension pediatric market. This market is currently valued at $625 million (as per IMS, Dec 2006). The incidence of respiratory infections is high in children and physicians need products that offer greater patient convenience and compliance," said Dr. Kamal Sharma, Managing Director, Lupin Ltd.

This is the Company's nineteenth ANDA approval till date.

About Lupin

Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the nine-month period ended December 2006, the Company's Revenues and Profit after Tax were Rs.14,985 million (US$ 335 million) and Rs.1,650 million (US$ 37 million) respectively.

For further information contact:
Raju Kane
The Source
Tel. +91 22 24901327/28
Telefax: +91 22 24901325
Mobile: +91 98200 45656
E-mail: rajukane@sourcepr.com